Skip to main content

Posts tagged with "Drug Industry History"

  • Drug Industry History

    Fall From Grace

    A couple of articles have come together and gotten me to thinking. Back during the summer, long-time medicinal chemist Mark Murcko published a short editorial in Drug Discovery Today comemmerating the Apollo 11 moon landing’s 40th anniversary: “People like me, who are old enough to actually remember the events of July 1969, are instantl… Read More
  • Business and Markets

    The Drug Business: A Turbulent Future?

    One of this blog’s regular correspondents has just been attending a chemistry outsourcing conference (program here), and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren’s a product of the Sharpless lab, who went on to Abbott, then Wall Street (Legg Mason and into the hed… Read More
  • Business and Markets

    Sepracor: A Desirable Property?

    Well, I didn’t see this one coming. Dainippon Sumitomo has announced that they’re buying Sepracor. My first thought on reading this was “Are they sure they want to do that?” I say that because the ostensible reason that the Japanese company is pulling out their wallet is that they’re looking to replace declining revenu… Read More
  • Chemical News

    Rings of the Future!

    Here’s an interesting paper that some of you may have seen in J. Med. Chem.: “Heteroaromatic Rings of the Future”. That’s an odd title, but an appropriate one. For the non-chemists in the crowd who made it to this paragraph, heteroaromatic rings are a very wide class of organic compounds. They’re flat cyclic structures… Read More
  • Cancer

    Thalidomide for Myeloma: Whose Idea Was It?

    So, if you’re a patient with a rare disease (or a relative of a patient with one), and you have an idea for repurposing an old drug for treatment. . .and you get a company interested, and it actually works. . .works to the point that the company takes in a billion or two dollars… Read More
  • Business and Markets

    Drug Companies Are Polar Bears? Maybe Not.

    There’s an interesting article up over at InVivoBlog, and I wanted to see what the readership here thought of its main premise. Subtracting out the cute ecological analogies (Big Pharma as polar bears, for example), you get to this: . . .For example, AstraZeneca, Novartis, and Bristol-Myers, all operate in the fields of neuroscience, oncology… Read More
  • Drug Development

    Spray-Painted For Success

    I do a lot of talking around here about how the general public doesn’t really have a good idea of what goes on inside a drug company. But a conversation with a colleague has put me to thinking that this might be largely our own fault. Consider the public face that our industry projects. Look… Read More
  • Business and Markets

    Pharma’s Return on Investment: Yikes

    There’s a recent article in Nature Reviews Drug Discovery that has some alarming figures in it. This is yet another look at the industry from McKinsey, and we’ll get to their McKinseyish solutions in a moment. But first, some numbers: They calculate that the return on investment (ROI) from small-molecule drug research was nearly 12% Read More
  • Academia (vs. Industry)

    Where Drugs Come From, and How. Once More, With A Roll of the Eyes

    I linked yesterday to a post by Megan McArdle about health care reform. And while I realize that everyone got into a shouting match in the comments to my own post on the subject – and people sure did in the comments to hers; it’s endemic – I wanted to quote a section from her… Read More
  • Alzheimer's Disease

    Amyloid in Trouble

    Here’s an interesting look at the current state of the Alzheimer’s field from Bloomberg. The current big hope is Wyeth (and Elan)’s bapineuzumab, which I last wrote about here. That was after the companies reported what had to be considered less-than-hoped-for efficacy in the clinic. The current trial is the one sorted out by APOE… Read More